retroviral proteases
Recently Published Documents


TOTAL DOCUMENTS

43
(FIVE YEARS 1)

H-INDEX

21
(FIVE YEARS 0)

Viruses ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 839
Author(s):  
Irene T. Weber ◽  
Yuan-Fang Wang ◽  
Robert W. Harrison

The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by drug resistance. This review covers the historical background of studies on the structure and function of HIV protease, the subsequent development of antiviral inhibitors, and recent studies on drug-resistant protease variants. We highlight the important contributions of Dr. Stephen Oroszlan to fundamental knowledge about the function of the HIV protease and other retroviral proteases. These studies, along with those of his colleagues, laid the foundations for the design of clinical inhibitors of HIV protease. The drug-resistant protease variants also provide an excellent model for investigating the molecular mechanisms and evolution of resistance.


2019 ◽  
Vol 75 (10) ◽  
pp. 904-917 ◽  
Author(s):  
Stanislaw Wosicki ◽  
Miroslaw Gilski ◽  
Helena Zabranska ◽  
Iva Pichova ◽  
Mariusz Jaskolski

Retroviral proteases (RPs) are of high interest owing to their crucial role in the maturation process of retroviral particles. RPs are obligatory homodimers, with a pepsin-like active site built around two aspartates (in DTG triads) that activate a water molecule, as the nucleophile, under two flap loops. Mason–Pfizer monkey virus (M-PMV) is unique among retroviruses as its protease is also stable in the monomeric form, as confirmed by an existing crystal structure of a 13 kDa variant of the protein (M-PMV PR) and its previous biochemical characterization. In the present work, two mutants of M-PMV PR, D26N and C7A/D26N/C106A, were crystallized in complex with a peptidomimetic inhibitor and one mutant (D26N) was crystallized without the inhibitor. The crystal structures were solved at resolutions of 1.6, 1.9 and 2.0 Å, respectively. At variance with the previous study, all of the new structures have the canonical dimeric form of retroviral proteases. The protomers within a dimer differ mainly in the flap-loop region, with the most extreme case observed in the apo structure, in which one flap loop is well defined while the other flap loop is not defined by electron density. The presence of the inhibitor molecules in the complex structures was assessed using polder maps, but some details of their conformations remain ambiguous. In all of the presented structures the active site contains a water molecule buried deeply between the Asn26-Thr27-Gly28 triads of the protomers. Such a water molecule is completely unique not only in retropepsins but also in aspartic proteases in general. The C7A and C106A mutations do not influence the conformation of the protein. The Cys106 residue is properly placed at the homodimer interface area for a disulfide cross-link, but the reducing conditions of the crystallization experiment prevented S—S bond formation. An animated Interactive 3D Complement (I3DC) is available in Proteopedia at http://proteopedia.org/w/Journal:Acta_Cryst_D:S2059798319011355.


FEBS Journal ◽  
2015 ◽  
Vol 282 (21) ◽  
pp. 4059-4066 ◽  
Author(s):  
Mariusz Jaskolski ◽  
Maria Miller ◽  
J. K. Mohana Rao ◽  
Alla Gustchina ◽  
Alexander Wlodawer
Keyword(s):  

Virology ◽  
2015 ◽  
Vol 479-480 ◽  
pp. 403-417 ◽  
Author(s):  
Jan Konvalinka ◽  
Hans-Georg Kräusslich ◽  
Barbara Müller
Keyword(s):  

2009 ◽  
Vol 17 (14) ◽  
pp. 5229-5237 ◽  
Author(s):  
Aleksejs Kontijevskis ◽  
Ramona Petrovska ◽  
Sviatlana Yahorava ◽  
Jan Komorowski ◽  
Jarl E.S. Wikberg

2009 ◽  
Vol 12 (10) ◽  
pp. 2173-2182 ◽  
Author(s):  
Marek Ingr ◽  
Tat'ána Uhlíková ◽  
Kvido Str̆ís̆ovský ◽  
Eva Majerová ◽  
Jan Konvalinka

2008 ◽  
Vol 82 (20) ◽  
pp. 10111-10117 ◽  
Author(s):  
Helga Eizert ◽  
Pálma Bander ◽  
Péter Bagossi ◽  
Tamás Sperka ◽  
Gabriella Miklóssy ◽  
...  

ABSTRACT The specificities of the proteases of 11 retroviruses were studied using a series of oligopeptides with amino acid substitutions in the P1, P3, and P4 positions of a naturally occurring type 1 cleavage site (Val-Ser-Gln-Asn-Tyr↓Pro-Ile-Val-Gln) in human immunodeficiency virus type 1 (HIV-1). Previously, the substrate specificity of the P2 site was studied for the same representative set of retroviral proteases, which included at least one member from each of the seven genera of the family Retroviridae (P. Bagossi, T. Sperka, A. Fehér, J. Kádas, G. Zahuczky, G. Miklóssy, P. Boross, and J. Tözsér, J. Virol. 79:4213-4218, 2005). Our enzyme set comprised the proteases of HIV-1, HIV-2, equine infectious anemia virus, avian myeloblastosis virus (AMV), Mason-Pfizer monkey virus, mouse mammary tumor virus (MMTV), Moloney murine leukemia virus, human T-lymphotropic virus type 1, bovine leukemia virus, walleye dermal sarcoma virus, and human foamy virus. Molecular models were used to interpret the similarities and differences in specificity between these retroviral proteases. The results showed that the retroviral proteases had similar preferences (Phe and Tyr) for the P1 position in this sequence context, but differences were found for the P3 and P4 positions. Importantly, the sizes of the P3 and P4 residues appear to be a major contributor for specificity. The substrate specificities correlated well with the phylogenetic tree of the retroviruses. Furthermore, while the specificities of some enzymes belonging to different genera appeared to be very similar (e.g., those of AMV and MMTV), the specificities of the primate lentiviral proteases substantially differed from that observed for a nonprimate lentiviral protease.


Sign in / Sign up

Export Citation Format

Share Document